VEGFA and hepatocellular carcinoma: The advent of immune checkpoint inhibitors (ICIs) and anti-angiogenic agents, such as atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)), has revolutionized first-line treatment for unresectable HCC.